RenBio
New York
About RenBio
RenBio develops antibody-based therapeutic solutions for the treatment of cancer and inflammatory diseases. RenBio's proprietary MYO technology involves in the development of antibody therapeutic that helps in treating rare diseases, viral infections, autoimmune diseases, and more by using DNA blueprint and antibody factory.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $43.9M
- Funding stage: Early Stage Venture
- Last round: Grant (Jul 2024)
- Website: renbio.com
- Phone: 1 (646) 440-9411
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/renbio-119556 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.